RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
31.66
+0.59 (+1.90%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close31.07
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume1,495,346
Market Cap222.286B
Beta0.49
PE Ratio (TTM)22.40
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.03 (3.31%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Global In Vitro Diagnostic Market Booms: Stocks in Focus
    Zacksyesterday

    Global In Vitro Diagnostic Market Booms: Stocks in Focus

    With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.

  • Company News For Nov 21, 2017
    Zacks2 days ago

    Company News For Nov 21, 2017

    Companies In The News are: DY,TWX,RHHBY,ITCI

  • Market Realist2 days ago

    Why Keytruda Could Boost Merck’s Revenue Growth in 2018

    In September 2017, the FDA approved Merck’s (MRK) Keytruda for the treatment of individuals with relapsing or recurrent metastatic GEJ (gastroesophageal junction) adenocarcinoma with PDL11-expressing tumors, ...

  • Roche Sues Pfizer to Bar Biosimilar of Cancer Drug Herceptin
    Bloomberg3 days ago

    Roche Sues Pfizer to Bar Biosimilar of Cancer Drug Herceptin

    Roche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block Pfizer Inc. from selling a copy of its breast-cancer drug ...

  • Why Roche Cancer Trial Is Kick In The Teeth For Dow Stock Merck
    Investor's Business Daily3 days ago

    Why Roche Cancer Trial Is Kick In The Teeth For Dow Stock Merck

    Roche is now a real competitor with a potential first treatment in advanced lung cancer, an analyst said Monday.

  • Roche's Two Good-News Scoops May Have a Short Shelf Life
    Bloomberg3 days ago

    Roche's Two Good-News Scoops May Have a Short Shelf Life

    Hemlibra and Tecentriq trial results are a near-term boon, but both face growing competition.

  • Barrons.com3 days ago

    Is Shire Bleeding Out?

    Today, Shire (SHPG) appointed a new chief financial officer. The shares are sliding lower today after its rival Roche (RHHBY) unveiled study results that showed its Hemlibra hemophilia drug trial reduced treated bleeds in hemophilia A patients without indicators. The news is an added blow for Shire.

  • Barrons.com3 days ago

    Roche: The Big Pipeline Payoff

    It isn’t every day that a major drug maker unveils a big clinical trial win. Roche Holding (RHHBY) shares were on the rise Monday after the company released data from two separate studies for its new cancer and hemophilia drugs. The immuno-cancer drug Tecentriq advanced as a treatment for advanced lung cancer when mixed with Roche’s other cancer drug Avastin and chemotherapy.

  • Roche Reports Positive Data From Tecentriq Combination Study
    Zacks3 days ago

    Roche Reports Positive Data From Tecentriq Combination Study

    Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

  • Reuters3 days ago

    Roche win boosts case for adding chemo to cancer immunotherapy

    Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.

  • Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss
    Zacks3 days ago

    Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss

    Political uncertainty in the United Kingdom and commodity prices weighed on Europe's stocks over last week.

  • Forbes3 days ago

    Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers

    Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said.

  • Reuters3 days ago

    Roche shares climb after trial wins in cancer, haemophilia

    Roche announced two trial wins for its cancer and haemophilia drugs on Monday, boosting its shares and weighing on the stocks of its main rivals. The Basel-based health group said its immunotherapy Tecentriq had made advances against lung cancer when mixed with other treatments, and its haemophilia agent Hemlibra had reduced bleeds in a new group of patients. Roche's shares rose as much as 5.6 percent, adding roughly $11 billion to its market capitalisation and making it the best performer on the Swiss Market Index.

  • TheStreet.com3 days ago

    Roche Stock Surges on Trial Successes in Cancer, Haemophilia

    Roche sees success in trials for its cancer and hemophilia drugs

  • Roche Shares Jump Following Successful Studies for Two Drugs
    Bloomberg4 days ago

    Roche Shares Jump Following Successful Studies for Two Drugs

    Roche Holding AG shares surged after two experimental medicines for cancer and hemophilia succeeded in much-anticipated patient trials, boding well for the Swiss drugmaker’s ability to grow as its biggest ...

  • Cancer Space Update: Label Expansion for Three Major Drugs
    Zacks6 days ago

    Cancer Space Update: Label Expansion for Three Major Drugs

    This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

  • Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval
    Zacks6 days ago

    Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

    Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

  • Reuters7 days ago

    Roche haemophilia drug wins FDA nod, with a warning

    The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for haemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. The U.S. regulator approved Roche's drug, previously known as ACE910, or emicizumab, as a once-weekly injection for adults and paediatric patients with haemophilia A who have developed inhibitors, or resistance, to other treatments.

  • Reuters7 days ago

    FDA backs Roche's Gazyva in first-line follicular lymphoma

    The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio ...

  • Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test
    Zacks8 days ago

    Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

    Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

  • Shire Gets Positive CHMP Opinion for Hemophilia A Drug
    Zacks9 days ago

    Shire Gets Positive CHMP Opinion for Hemophilia A Drug

    Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

  • Amgen Gets Positive CHMP Opinion to Expand Nplate's Label
    Zacks10 days ago

    Amgen Gets Positive CHMP Opinion to Expand Nplate's Label

    Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.

  • Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
    Zacks13 days ago

    Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

    Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

  • Reuters13 days ago

    Roche MS drug Ocrevus wins European panel backing

    Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for nearly $1 billion in sales in 2017 after winning U.S. regulators' go-ahead earlier this year. Ocrevus got a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating adult patients with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS). Final approval falls to the European Commission, but it generally follows the CHMP recommendation.

  • Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss
    Zacks14 days ago

    Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

    Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.